Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Instagram Outage Disrupts Thousands of U.S. Users 
TEMPLE CITY, Calif., Nov. 15, 2016 -- Fulgent Genetics, Inc. (Nasdaq:FLGT) today announced that Ming Hsieh, Chairman and Chief Executive Officer, and Paul Kim, Chief Financial Officer, are scheduled to participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference at the Lotte New York Palace hotel on Tuesday, November 29, 2016 at 10:00 AM Eastern Time.
The live audio webcast can be accessed in the Investor Relations section of the company’s website, www.fulgentgenetics.com. An audio replay of the webcast will remain available on the company’s website through December 29, 2016.
About Fulgent Genetics, Inc.
Fulgent Genetics is a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive leaning software, advanced genetic diagnostic tools, and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy, and competitive turnaround times. The company believes its current test menus, which includes more than 18,000 single-gene tests and more than 250 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Contact: The Blueshirt Group Bob Jones, 212- 871-5570, [email protected]
